The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program
Year: 2020
Type: article
Institutions: The University of Sydney, Royal Prince Alfred Hospital, UNSW Sydney, The George Institute for Global Health, University Medical Center Groningen, University of Groningen, Royal North Shore Hospital, Saint Luke's Hospital, National University Heart Centre Singapore, National Heart Centre Singapore, Brigham and Women's Hospital, Baim Institute for Clinical Research, Janssen Research & Development (United States), Stanford Medicine, Stanford University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: canagliflozin, SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, cardiovascular risk, cardiometabolic biomarkers, HbA1c, systolic blood pressure, body weight, urinary albumin-creatinine ratio, estimated glomerular filtration rate, major adverse cardiac events, combination therapy, synergistic effect, CANVAS Program
Open Access status: bronze
Funders: Heart Foundation, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, AbbVie, Boehringer Ingelheim, Boston Scientific Corporation, Heart Research Australia, University of New South Wales, Novo Nordisk, Astellas Pharma, Vifor Pharma, Servier, Abbott Diagnostics, National Health and Medical Research Council, National Medical Research Council, Relypsa, Janssen Research and Development
Awards: G2729279464, G8387966140
OpenAlex ID: W3036492162
